ALNY Alnylam Pharmaceuticals Loading... : Bullish and Bearish Analyst Opinions

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
19:52
Jul 09
Martin Shkreli Investor / Podcast host
Author mentions covering a position in ALNY early, no current directional view or catalyst.
ALNY
LOW
12:13
Jul 09
zerohedge Financial blog / news aggregator
Premarket movers report shows mixed Mag 7 stocks.
Premarket movers report shows mixed Mag 7 stocks, with notable gains for CECO on JPMorgan initiation, ALNY and BBIO on rival drug trial failure, and SMPL on earnings beat, while IBM, IONS, LEVI, MAT, and CRM decline on various negative catalysts.
ALNY
12:21
Jun 15
TheValueist Founder, Atlas Peak Research
Watch these companies as top contenders for next quarter’s S&P 500 addition if profitability.
Watch these companies as top contenders for next quarter’s S&P 500 addition if profitability improves.
ALNY
MED
21:30
Feb 10
Daniel O'Day CEO, Gilead Sciences, Inc. GILD Q4 FY25 call
Gilead's BD focus could target RNAi or other modalities where Alnylam is a leader, though no specific deal mentioned.
ALNY
LOW

About ALNY Analyst Coverage

Buzzberg tracks ALNY (Alnylam Pharmaceuticals) across 4 sources. 0 bullish vs 0 bearish calls from 4 analysts. Sentiment: evenly split. 4 total trade ideas tracked. Latest voices: Martin Shkreli, zerohedge, TheValueist.